tenofovir + emtricitabine + atazanavir-ritonavir — Competitive Intelligence Brief

tenofovir + emtricitabine + atazanavir-ritonavir (tenofovir + emtricitabine + atazanavir-ritonavir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (NRTI + PI/r). Area: Infectious Disease / Virology.

marketed Antiretroviral combination (NRTI + PI/r) HIV reverse transcriptase, HIV protease Infectious Disease / Virology Small molecule

Target snapshot

tenofovir + emtricitabine + atazanavir-ritonavir (tenofovir + emtricitabine + atazanavir-ritonavir) — Juan A. Arnaiz. This combination inhibits HIV reverse transcriptase and protease to block viral replication at multiple steps.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
tenofovir + emtricitabine + atazanavir-ritonavir TARGET	tenofovir + emtricitabine + atazanavir-ritonavir	Juan A. Arnaiz	marketed	Antiretroviral combination (NRTI + PI/r)	HIV reverse transcriptase, HIV protease
Highly active antiretroviral therapy	Highly active antiretroviral therapy	PETHEMA Foundation	marketed	Antiretroviral combination therapy	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen composition)
Standard-of-care Antiretroviral therapy	Standard-of-care Antiretroviral therapy	Medical Research Council	marketed	Antiretroviral combination therapy (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitors)	HIV reverse transcriptase, HIV protease, HIV integrase, HIV envelope glycoproteins (CCR5/CXCR4 co-receptors)
Standard Triple	Standard Triple	University of Alberta	marketed	Antiretroviral combination therapy	HIV reverse transcriptase, HIV protease (depending on formulation)
Rilpivirine + darunavir/cobicistat	Rilpivirine + darunavir/cobicistat	A.O. Ospedale Papa Giovanni XXIII	marketed	Antiretroviral combination (NNRTI + protease inhibitor + pharmacokinetic booster)	HIV reverse transcriptase, HIV protease
Tenofovir + emtricitabine + lopinavir/ritonavir	Tenofovir + emtricitabine + lopinavir/ritonavir	Juan A. Arnaiz	marketed	Antiretroviral combination (NRTI + protease inhibitor)	HIV reverse transcriptase, HIV protease
emtricitabine, darunavir/cobicistat, maraviroc	emtricitabine, darunavir/cobicistat, maraviroc	Giovanni Di Perri	marketed	Antiretroviral combination (NRTI + PI + pharmacokinetic booster + CCR5 antagonist)	HIV reverse transcriptase, HIV protease, CYP3A4, CCR5 co-receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (NRTI + PI/r) class)

1. Juan A. Arnaiz · 1 drug in this class